ERAXIS

This brand name is authorized in Canada, Hong Kong, Israel, Singapore, United States, South Africa

Active ingredients

The drug ERAXIS contains one active pharmaceutical ingredient (API):

1 Anidulafungin UNII 9HLM53094I - ANIDULAFUNGIN

Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fermentation product of Aspergillus nidulans. Anidulafungin selectively inhibits 1,3-β-D glucan synthase, an enzyme present in fungal, but not mammalian cells. Read about Anidulafungin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ERAXIS Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J02AX06	Anidulafungin	J Antiinfectives for systemic use → J02 Antimycotics for systemic use → J02A Antimycotics for systemic use → J02AX Other antimycotics for systemic use
Discover more medicines within J02AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02330695
Country: HK	Department of Health Drug Office	Identifier(s): 57097, 59270
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 6403
Country: SG	Health Sciences Authority	Identifier(s): 13585P
Country: US	FDA, National Drug Code	Identifier(s): 0049-0114, 0049-0116
Country: ZA	Health Products Regulatory Authority	Identifier(s): 44/20.1.7/0355